Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study
Jie Mei(Sun Yat-sen University), Rong Guo(Sun Yat-sen University), Yihong Ling(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Jingwen Zou(Sun Yat-sen University), Wen‐Ping Lin(Sun Yat-sen University), Yuhua Wen(Tongji University), Lianghe Lu(Sun Yat-sen University), Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Qiaoxuan Wang(Institute of Polymers)
Cited by 17
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome
|European Journal of Endocrinology|2011|160